首页> 美国卫生研究院文献>Wiley-Blackwell Online Open >Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses
【2h】

Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses

机译:新型USPIO GEH121333对癌症免疫反应的MR成像的评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tumor-associated macrophages (TAM) maintain a chronic inflammation in cancers, which is associated with tumor aggressiveness and poor prognosis. The purpose of this study was to: (1) evaluate the pharmacokinetics and tolerability of the novel ultrasmall superparamagnetic iron oxide nanoparticle (USPIO) compound GEH121333; (2) assess whether GEH121333 can serve as a MR imaging biomarker for TAM; and (3) compare tumor MR enhancement profiles between GEH121333 and ferumoxytol. Blood half-lives of GEH121333 and ferumoxytol were measured by relaxometry (n = 4 each). Tolerance was assessed in healthy rats injected with high dose GEH121333, vehicle or saline (n = 4 each). Animals were monitored for 7 days regarding body weight, complete blood counts and serum chemistry, followed by histological evaluation of visceral organs. MR imaging was performed on mice harboring MMTV-PyMT-derived breast adenocarcinomas using a 7 T scanner before and up to 72 h post-injection (p.i.) of GEH121333 (n = 10) or ferumoxytol (n = 9). Tumor R1, R2* relaxation rates were compared between different experimental groups and time points, using a linear mixed effects model with a random effect for each animal. MR data were correlated with histopathology. GEH121333 showed a longer circulation half-life than ferumoxytol. Intravenous GEH121333 did not produce significant adverse effects in rats. All tumors demonstrated significant enhancement on T1, T2 and T2*-weighted images at 1, 24, 48 and 72 h p.i. GEH121333 generated stronger tumor T2* enhancement than ferumoxytol. Histological analysis verified intracellular compartmentalization of GEH121333 by TAM at 24, 48 and 72 h p.i. MR imaging with GEH121333 nanoparticles represents a novel biomarker for TAM assessment. This new USPIO MR contrast agent provides a longer blood half-life and better TAM enhancement compared with the iron supplement ferumoxytol. Copyright © 2013 John Wiley & Sons, Ltd.Supporting information may be found in the online version of this paper
机译:肿瘤相关巨噬细胞(TAM)在癌症中维持慢性炎症,这与肿瘤侵袭性和不良预后有关。这项研究的目的是:(1)评价新型超小型超顺磁性氧化铁纳米粒子(USPIO)化合物GEH121333的药代动力学和耐受性; (2)评估GEH121333是否可以作为TAM的MR成像生物标记物; (3)比较GEH121333和阿魏酸之间的肿瘤MR增强特征。 GEH121333和阿魏酸的血液半衰期通过弛豫法测量(每个n = 4)。在注射高剂量GEH121333,溶媒或生理盐水(每组n = 4)的健康大鼠中评估耐受性。监测动物7天的体重,全血细胞计数和血清化学,随后对内脏器官进行组织学评估。在注射(p.i.)GEH121333(n = 10)或阿魏三醇(n = 9)之前和之后72小时,使用7 T扫描仪对携带MMTV-PyMT来源的乳腺腺癌的小鼠进行MR成像。使用线性混合效应模型对每只动物随机产生的影响,比较不同实验组和时间点之间的肿瘤R1,R2 *松弛率。 MR数据与组织病理学相关。 GEH121333的循环半衰期比阿魏酸更长。静脉内GEH121333在大鼠中未产生明显的不良反应。在第1、24、48和72 h p.i,所有肿瘤在T1,T2和T2 *加权图像上均显示出明显的增强。 GEH121333产生的肿瘤T2 *增强作用强于阿魏酸。组织学分析证实了TAM在24、48和72 h p.i时GEH121333的细胞内区室化。 GEH121333纳米粒子的MR成像代表了TAM评估的新型生物标记。与铁补充阿魏酸相比,这种新的USPIO MR造影剂具有更长的血液半衰期和更好的TAM增强作用。版权所有©2013 John Wiley&Sons,Ltd.可以在本文的在线版本中找到支持信息

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号